Abstract
Recent evidence indicates that vascular endothelial growth factor (VEGF) is capable of protecting dopaminergic (DA) neurons. Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by the degeneration of nigrostriatal dopaminergic neurons. To evaluate the role of VEGF single nucleotide polymorphisms (SNPs) and haplotypes in PD, we performed a case–control study including 400 PD patients and 400 healthy-matched controls. Polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) analysis and DNA sequencing were used to detect the rs699947, rs2010963 and rs3025039 polymorphisms of the VEGF gene in cases and controls. Our study revealed that T allelic frequency of rs3025039 polymorphism was significantly higher in PD subjects (OR 1.497, 95 % CI 1.099–2.040, P = 0.013) than that in controls. Significant association for rs3025039 could be found in additive model (TT vs. CT vs. CC: OR 1.489, 95 % CI 1.018–2.177, P = 0.040) and dominant model (TT + CT vs. CC: OR 1.538, 95 % CI 1.068–2.216, P = 0.021). Subgroup analyses performed by gender suggested that this association could be found in male, but not in female. Moreover, it also demonstrated a significant association in the subgroup of late-onset PD (LOPD). However, for rs699947 and rs2010963 polymorphisms, genotype or allele frequencies did not differ between groups. No significant association could be found between rs699947 and rs2010963 polymorphism and PD risk. None of the observed haplotypes showed significant association with PD. Therefore, these results suggested that the VEGF gene might be associated with risk of developing sporadic PD in Han Chinese and the rs3025039 polymorphism may be a risk factor for sporadic PD.
Similar content being viewed by others
References
Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144. doi:10.1016/j.freeradbiomed.2013.01.018
Bartels AL, Leenders KL (2009) Parkinson’s disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45(8):915–921. doi:10.1016/j.cortex.2008.11.010
Rosenstein JM, Krum JM (2004) New roles for VEGF in nervous tissue–beyond blood vessels. Exp Neurol 187(2):246–253. doi:10.1016/j.expneurol.2004.01.022
Storkebaum E, Carmeliet P (2004) VEGF: a critical player in neurodegeneration. J Clin Investig 113(1):14–18. doi:10.1172/jci20682
Quittet MS, Touzani O, Sindji L, Cayon J, Fillesoye F, Toutain J, Divoux D, Marteau L, Lecocq M, Roussel S, Montero-Menei CN, Bernaudin M (2015) Effects of mesenchymal stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat. Acta Biomater 15:77–88. doi:10.1016/j.actbio.2014.12.017
Krum JM, Mani N, Rosenstein JM (2008) Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Exp Neurol 212(1):108–117. doi:10.1016/j.expneurol.2008.03.019
Nowacka MM, Obuchowicz E (2012) Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides 46(1):1–10. doi:10.1016/j.npep.2011.05.005
Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neuro-Signals 14(5):207–221. doi:10.1159/000088637
Falk T, Yue X, Zhang S, McCourt AD, Yee BJ, Gonzalez RT, Sherman SJ (2011) Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson’s disease. Neurosci Lett 496(1):43–47. doi:10.1016/j.neulet.2011.03.088
Piltonen M, Planken A, Leskela O, Myohanen TT, Hanninen AL, Auvinen P, Alitalo K, Andressoo JO, Saarma M, Mannisto PT (2011) Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo. Neuroscience 192:550–563. doi:10.1016/j.neuroscience.2011.06.084
Yasuhara T, Shingo T, Muraoka K, Wen Ji Y, Kameda M, Takeuchi A, Yano A, Nishio S, Matsui T, Miyoshi Y, Hamada H, Date I (2005) The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson’s disease model. Brain Res 1038(1):1–10. doi:10.1016/j.brainres.2004.12.055
Yasuda T, Fukuda-Tani M, Nihira T, Wada K, Hattori N, Mizuno Y, Mochizuki H (2007) Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson’s disease. Exp Neurol 206(2):308–317. doi:10.1016/j.expneurol.2007.05.012
Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I (2005) Neurorescue effects of VEGF on a rat model of Parkinson’s disease. Brain Res 1053(1–2):10–18. doi:10.1016/j.brainres.2005.05.027
Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46(3):293–298. doi:10.1016/j.lungcan.2004.04.037
Samli H, Demir BC, Ozgoz A, Atalay MA, Uncu G (2012) Vascular endothelial growth factor gene 1154 G/A, 2578 C/A, 460 C/T, 936 C/T polymorphisms and association with recurrent pregnancy losses. Genet Mol Res: GMR 11(4):4739–4745. doi:10.4238/2012.December.17.6
Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8):1232–1235. doi:10.1006/cyto.2000.0692
Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106(4):468–471. doi:10.1002/ijc.11238
Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, Virgilio R, Galimberti D, Galimberti G, Crimi M, Ferrarese C, Scarpini E, Bresolin N, Comi GP (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57(3):373–380. doi:10.1002/ana.20390
Terry PD, Kamel F, Umbach DM, Lehman TA, Hu H, Sandler DP, Taylor JA (2004) VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J Neurogenet 18(2):429–434. doi:10.1080/01677060490894450
Mihci E, Ozkaynak SS, Sallakci N, Kizilay F, Yavuzer U (2011) VEGF polymorphisms and serum VEGF levels in Parkinson’s disease. Neurosci Lett 494(1):1–5. doi:10.1016/j.neulet.2011.02.027
Kim JS, Yim SV, Koh IS, Choi JS, Yoo JY, Lee KS, Lim Y, Lee KH (2009) Single-nucleotide polymorphisms (SNPs) and haplotype analysis in vascular endothelial growth factor (VEGF) gene in the patients with Parkinson disease and lung cancer. Arch Gerontol Geriatr 48(3):287–290. doi:10.1016/j.archger.2008.02.007
Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP (2009) VEGF genetic variability is associated with increased risk of developing Alzheimer’s disease. J Neurol Sci 283(1–2):66–68. doi:10.1016/j.jns.2009.02.318
Yuan Q, Zuo X, Jia J (2009) Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer’s disease among Northern Chinese Han. Neurosci Lett 457(3):133–136. doi:10.1016/j.neulet.2009.03.078
Chapuis J, Tian J, Shi J, Bensemain F, Cottel D, Lendon C, Amouyel P, Mann D, Lambert JC (2006) Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer’s disease. Neurobiol Aging 27(9):1212–1215. doi:10.1016/j.neurobiolaging.2005.07.013
Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Sanchez-Quintana C, Sanchez-Juan P, Berciano J, Combarros O (2006) Case–control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer’s disease. Neurosci Lett 401(1–2):171–173. doi:10.1016/j.neulet.2006.03.020
Vught PWV, Sutedja NA, Veldink JH, Koeleman BP, Groeneveld GJ, Wijmenga C, Uitdehaag BM, Jong JMD, Baas F, Wokke JH, Berg LHVD (2005) Lack of association between VEGF polymorphisms and ALS in a Dutch population. Neurology 22:1643–1645
Acknowledgments
We are grateful to all of the subjects who kindly agreed to participate in this study. This work was supported by Chinese National Human Genome Center, Beijing. We extend our gratitude to the reviewers for their helpful comments on this paper. This work was supported by grants from Natural Science Foundation of China (81571225).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Wu, Y., Zhang, Y., Han, X. et al. Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurol Sci 37, 1923–1929 (2016). https://doi.org/10.1007/s10072-016-2691-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-016-2691-x